Several big-name activists have been unsuccessful in shaping the corporate landscape by stopping mergers they oppose, a new report details.
Starboard Value couldn’t stop Bristol-Myers Squibb from taking over Celgene, and neither Pershing Square Capital Management nor Third Point had any success in stopping United Technologies from its plans to acquire Raytheon.
